• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

抗真菌药敏试验的临床应用

Clinical utility of antifungal susceptibility testing.

作者信息

McCarty Todd P, Luethy Paul M, Baddley John W, Pappas Peter G

机构信息

Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA.

Department of Pathology, University of Maryland, Baltimore, MD, USA.

出版信息

JAC Antimicrob Resist. 2022 Jun 28;4(3):dlac067. doi: 10.1093/jacamr/dlac067. eCollection 2022 Jun.

DOI:10.1093/jacamr/dlac067
PMID:35774069
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9237445/
Abstract

Invasive fungal diseases cause significant morbidity and mortality, in particular affecting immunocompromised patients. Resistant organisms are of increasing importance, yet there are many notable differences in the ability to both perform and interpret antifungal susceptibility testing compared with bacteria. In this review, we will highlight the strengths and limitations of resistance data of pathogenic yeasts and moulds that may be used to guide treatment and predict clinical outcomes.

摘要

侵袭性真菌病会导致严重的发病和死亡,尤其会影响免疫功能低下的患者。耐药菌的重要性日益增加,然而与细菌相比,在进行和解释抗真菌药敏试验的能力方面存在许多显著差异。在这篇综述中,我们将强调致病性酵母和霉菌耐药数据的优势和局限性,这些数据可用于指导治疗并预测临床结果。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0c6d/9237445/9290249ca3cb/dlac067f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0c6d/9237445/9290249ca3cb/dlac067f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0c6d/9237445/9290249ca3cb/dlac067f1.jpg

相似文献

1
Clinical utility of antifungal susceptibility testing.抗真菌药敏试验的临床应用
JAC Antimicrob Resist. 2022 Jun 28;4(3):dlac067. doi: 10.1093/jacamr/dlac067. eCollection 2022 Jun.
2
Candida and candidaemia. Susceptibility and epidemiology.念珠菌与念珠菌血症。药敏性与流行病学。
Dan Med J. 2013 Nov;60(11):B4698.
3
Role of antifungal susceptibility testing in patient management.抗真菌药敏试验在患者管理中的作用。
Curr Opin Infect Dis. 2006 Dec;19(6):538-43. doi: 10.1097/QCO.0b013e328010682c.
4
Current status of antifungal resistance and its impact on clinical practice.抗真菌药物耐药现状及其对临床实践的影响。
Br J Haematol. 2014 Aug;166(4):471-84. doi: 10.1111/bjh.12896. Epub 2014 Apr 18.
5
Resistance in human pathogenic yeasts and filamentous fungi: prevalence, underlying molecular mechanisms and link to the use of antifungals in humans and the environment.人类致病酵母和丝状真菌的耐药性:流行情况、潜在分子机制以及与人类和环境中抗真菌药物使用的关联
Dan Med J. 2016 Oct;63(10).
6
Invasive candidiasis and the utility of antifungal susceptibility testing in the ICU.重症监护病房中的侵袭性念珠菌病及抗真菌药敏试验的应用
J Pharm Pract. 2010 Feb;23(1):33-7. doi: 10.1177/0897190009356552.
7
Antifungal susceptibility of invasive yeast isolates in Italy: the GISIA3 study in critically ill patients.意大利侵袭性酵母分离株的抗真菌药敏性:危重症患者中的 GISIA3 研究。
BMC Infect Dis. 2011 May 17;11:130. doi: 10.1186/1471-2334-11-130.
8
Significance of molecular identification and antifungal susceptibility of clinically significant yeasts and moulds in a global antifungal surveillance programme.在一项全球抗真菌监测计划中,临床重要酵母菌和霉菌的分子鉴定和抗真菌药敏性的意义。
Mycopathologia. 2012 Oct;174(4):259-71. doi: 10.1007/s11046-012-9551-x. Epub 2012 May 13.
9
Fungal susceptibility testing: where are we now?真菌药敏试验:我们目前的进展如何?
Transpl Infect Dis. 2002;4 Suppl 3:38-45. doi: 10.1034/j.1399-3062.4.s3.6.x.
10
Fungal-specific Cyp51 inhibitor VT-1598 demonstrates in vitro activity against Candida and Cryptococcus species, endemic fungi, including Coccidioides species, Aspergillus species and Rhizopus arrhizus.真菌特异性细胞色素 P45051 抑制剂 VT-1598 对念珠菌属和隐球菌属等致病真菌、地方性真菌(包括粗球孢子菌属、曲霉属和根毛霉属)具有体外活性。
J Antimicrob Chemother. 2018 Feb 1;73(2):404-408. doi: 10.1093/jac/dkx410.

引用本文的文献

1
FungAMR: a comprehensive database for investigating fungal mutations associated with antimicrobial resistance.真菌抗菌药物耐药性:一个用于研究与抗菌药物耐药性相关真菌突变的综合数据库。
Nat Microbiol. 2025 Aug 11. doi: 10.1038/s41564-025-02084-7.
2
Antifungal Resistance in Non-fumigatus Aspergillus Species.非烟曲霉属真菌中的抗真菌耐药性
Mycoses. 2025 Apr;68(4):e70051. doi: 10.1111/myc.70051.
3
Comparative evaluation of antifungal susceptibility testing methods of invasive Candida species and detection of FKS genes mutations in caspofungin intermediate and resistant isolates.

本文引用的文献

1
Antifungal Resistance Trends of Candida auris Clinical Isolates in New York and New Jersey from 2016 to 2020.2016 年至 2020 年纽约和新泽西州耳念珠菌临床分离株的抗真菌耐药趋势。
Antimicrob Agents Chemother. 2022 Mar 15;66(3):e0224221. doi: 10.1128/aac.02242-21. Epub 2022 Jan 10.
2
Coronavirus Disease 2019-Associated Invasive Fungal Infection.2019冠状病毒病相关侵袭性真菌感染
Open Forum Infect Dis. 2021 Nov 16;8(12):ofab510. doi: 10.1093/ofid/ofab510. eCollection 2021 Dec.
3
Molecular Mechanisms of 5-Fluorocytosine Resistance in Yeasts and Filamentous Fungi.
侵袭性念珠菌属抗真菌药敏试验方法的比较评估以及卡泊芬净中介和耐药菌株中FKS基因突变的检测
BMC Infect Dis. 2025 Jan 24;25(1):114. doi: 10.1186/s12879-024-10435-8.
4
Antifungal Activity of (Kunth) Mez Essential Oil and Its Main Compound 1-Nitro-2-Phenylethane against Dermatophytes.(昆斯)梅兹精油及其主要成分1-硝基-2-苯乙烷对皮肤癣菌的抗真菌活性。
Antibiotics (Basel). 2024 May 24;13(6):488. doi: 10.3390/antibiotics13060488.
5
Case report: Diagnostic and therapeutic challenges of fungal endocarditis by in a child with congenital heart defects.病例报告:先天性心脏病患儿真菌性心内膜炎的诊断与治疗挑战
Front Pediatr. 2023 Oct 6;11:1200215. doi: 10.3389/fped.2023.1200215. eCollection 2023.
6
[Research advances on invasive fungal infections after burns].[烧伤后侵袭性真菌感染的研究进展]
Zhonghua Shao Shang Yu Chuang Mian Xiu Fu Za Zhi. 2023 Mar 20;39(3):269-274. doi: 10.3760/cma.j.cn501225-20220523-00199.
7
A study of the association between virulence factors and antifungal susceptibility profile of species recovered from cases of vulvovaginal candidiasis.一项关于从外阴阴道念珠菌病病例中分离出的菌株的毒力因子与抗真菌药敏谱之间关联的研究。
J Family Med Prim Care. 2023 Jan;12(1):152-159. doi: 10.4103/jfmpc.jfmpc_1479_22. Epub 2023 Feb 15.
8
Section and Antifungals: From Broth to Agar-Based Susceptibility Testing Methods.章节与抗真菌药物:从肉汤到基于琼脂的药敏试验方法
J Fungi (Basel). 2023 Feb 27;9(3):306. doi: 10.3390/jof9030306.
9
A Practical Guide to Antifungal Susceptibility Testing.抗真菌药敏试验实用指南。
J Pediatric Infect Dis Soc. 2023 Apr 28;12(4):214-221. doi: 10.1093/jpids/piad014.
10
Severe Sporotrichosis Caused by Sporothrix brasiliensis: Antifungal Susceptibility and Clinical Outcomes.巴西孢子丝菌引起的重症孢子丝菌病:抗真菌药敏性及临床结局
J Fungi (Basel). 2022 Dec 28;9(1):49. doi: 10.3390/jof9010049.
酵母和丝状真菌中5-氟胞嘧啶耐药性的分子机制
J Fungi (Basel). 2021 Oct 27;7(11):909. doi: 10.3390/jof7110909.
4
COVID-19-associated mucormycosis: Evidence-based critical review of an emerging infection burden during the pandemic's second wave in India.COVID-19 相关毛霉病:大流行第二波期间印度新兴感染负担的循证批判性综述。
PLoS Negl Trop Dis. 2021 Nov 18;15(11):e0009921. doi: 10.1371/journal.pntd.0009921. eCollection 2021 Nov.
5
Antifungal Susceptibility Testing: A Primer for Clinicians.抗真菌药敏试验:临床医生入门指南。
Open Forum Infect Dis. 2021 Sep 9;8(11):ofab444. doi: 10.1093/ofid/ofab444. eCollection 2021 Nov.
6
The Antifungal Pipeline: Fosmanogepix, Ibrexafungerp, Olorofim, Opelconazole, and Rezafungin.抗真菌药物管线上的药物:福沙那韦、依柏西普、奥洛福康唑、泊沙康唑和瑞他康唑。
Drugs. 2021 Oct;81(15):1703-1729. doi: 10.1007/s40265-021-01611-0. Epub 2021 Oct 9.
7
In vitro activity of ibrexafungerp against Candida species isolated from blood cultures. Determination of wild-type populations using the EUCAST method.体外伊布康唑对血培养分离的念珠菌属的活性。使用 EUCAST 方法测定野生型人群。
Clin Microbiol Infect. 2022 Jan;28(1):140.e1-140.e4. doi: 10.1016/j.cmi.2021.09.030. Epub 2021 Oct 4.
8
Antifungal Susceptibility of 182 Fusarium Species Isolates from 20 European Centers: Comparison between EUCAST and Gradient Concentration Strip Methods.来自 20 个欧洲中心的 182 种镰刀菌属真菌分离株的抗真菌药敏性:EUCAST 和梯度浓度条带法的比较。
Antimicrob Agents Chemother. 2021 Nov 17;65(12):e0149521. doi: 10.1128/AAC.01495-21. Epub 2021 Sep 20.
9
Epidemiology and Antifungal Susceptibilities of Mucoralean Fungi in Clinical Samples from the United States.美国临床样本中毛霉目真菌的流行病学和抗真菌药敏性。
J Clin Microbiol. 2021 Aug 18;59(9):e0123021. doi: 10.1128/JCM.01230-21.
10
Antimicrobial activity of manogepix, a first-in-class antifungal, and comparator agents tested against contemporary invasive fungal isolates from an international surveillance programme (2018-2019).抗真菌新药马尼格匹克斯对国际监测项目(2018-2019 年)中分离的当代侵袭性真菌的抗菌活性及其与对照药物的比较。
J Glob Antimicrob Resist. 2021 Sep;26:117-127. doi: 10.1016/j.jgar.2021.04.012. Epub 2021 May 26.